Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSonoMotion

About this trial

This is a prospective, open-label, multi-center, single-arm (non-randomized) study to assess the safety and effectiveness of breaking stones in the upper urinary tract using the SonoMotion Break Wave technology. Up to 30 subjects will be included. The procedure will be performed in a hospital surgical environment as an outpatient (without being admitted) or in a non-surgical environment such as a clinic or office procedure room. The procedure will be performed under varying levels of anesthesia ranging from no anesthesia to general anesthesia (fully asleep). Stones will be limited to ≤ 10 mm for lower pole stones and ≤ 20 mm everywhere else.

Safety will be measured by the self-reported occurrences of adverse events, unplanned emergency department or clinic visits, and the need for further intervention. Fragmentation will be measured by self-reported stone passage and a comparison of computed tomography (CT) images before and after the procedure.

Eligibility criteria

Qualifiers

Individuals presenting with at least one kidney stone apparent on CT.

Stones must be within the upper urinary tract.

Stones are indicated for SWL treatment per the American Urology Association (AUA) 2016 guidelines.8

Stones must be measured under CT to be within the AUA 2016 SWL guidelines (i.e. ≤ 10 mm for lower pole stones and ≤ 20 mm for non-lower pole stones).

Disqualifiers

Acute untreated urinary tract infection or urosepsis.

Uncorrected bleeding disorders or coagulopathies.

Pregnancy.

Uncorrected obstruction distal to the stone.

Trial design

Treatments tested in this trial

  • Break Wave extracorporeal lithotripsy

Treatment groups

70 Participants
are divided into 1 treatment group

Sponsors and collaborators

SonoMotion

Lead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator